Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 11/20 | 0.81 |
| ▸ | SRD5A1 | P18405 | 10/20 | 0.81 |
| ▸ | CDC25A | P30304 | 5/20 | 0.57 |
| ▸ | FNTA | P49354 | 4/20 | 0.55 |
| ▸ | FNTB | P49356 | 4/20 | 0.55 |
| ▸ | CDC45 | O75419 | 1/20 | 0.52 |
| ▸ | PTPRC | P08575 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812015 | 1.00 | SRD5A2 (0.81) | SRD5A2SRD5A1CDC25AFNTAFNTB | |
| SCHEMBL916930 | 1.00 | SRD5A2 (0.81) | SRD5A2SRD5A1CDC25AFNTAFNTB | |
| SCHEMBL1587376 | 0.91 | SRD5A2 (0.84) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL8931523 | 0.91 | SRD5A2 (0.84) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL913647 | 0.91 | SRD5A2 (0.84) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL913644 | 0.91 | SRD5A2 (0.84) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL918268 | 0.90 | SRD5A1 (0.86) | SRD5A2SRD5A1 | |
| SCHEMBL918267 | 0.90 | SRD5A1 (0.86) | SRD5A2SRD5A1 | |
| SCHEMBL917095 | 0.90 | SRD5A2 (1.00) | SRD5A2SRD5A1FNTAFNTB | |
| SCHEMBL8931520 | 0.90 | SRD5A1 (0.86) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | claimed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | claimed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | claimed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0572165-B1 | New 7B-substituted-4-aza-5a-cholestan-ones as 5a-reductase inhibitors | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995013815-A1 | COMBINATION METHOD FOR THE TREATMENT OF PATTERNED ALOPECIA | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | claimed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | claimed |
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-1995013077-A1 | 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-3-ONES AS SELECTIVE 5α-REDUCTASE 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | ADRA1D, ADRB1, AGER | SRD5A2 26/4885SRD5A1 17/4885CDC25A 3394/4885 |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | SRD5A2 26/4885SRD5A1 17/4885CDC25A 3394/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | SRD5A2 4/4885SRD5A1 10/4885CDC25A 4347/4885 |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | ADRA1D, ADRB1, AGER | SRD5A2 53/4885SRD5A1 37/4885CDC25A 3541/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | SRD5A2 4/4885SRD5A1 10/4885CDC25A 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.